Stable gene transfer to the nervous system using a non-primate lentiviral vector

Gene Therapy

Volumn 6, Issue 11, 1999, Pages 1808-1818

  Mitrophanous, K A ^a   Yoon, S ^b   Rohll, J B ^a   Patil, D ^b   Wilkes, F J ^a   Kim, V N ^b   Kingsman, S M ^a,b   Kingsman, A J ^a,b   Mazarakis, N D ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CNS; dUTPase; EIAV; Lentiviral retroviral vectors; Rabies G; S2

Indexed keywords

DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; GAG PROTEIN; POL PROTEIN; REV PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EQUINE INFECTIOUS ANEMIA VIRUS; FEMALE; GENE TARGETING; GENE TRANSFER; GLIA; HIPPOCAMPUS; HUMAN; HUMAN CELL; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS TYPING;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; LENTIVIRUS; PRIMATES;

EID: 0032757387     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301023     Document Type: Article

References (50)

1. Fields BN, Knipe DM, Howley PM. In: Chanock RM et al (eds). Fields Virology, 3rd edn, Vol. 2. Lippincott-Raven Publishers: Philadelphia, 1996, pp 1977-1996.
2. Lever AML. HIV and other lentivirus-based vectors. Gene Therapy 1996; 3: 470-471.
3. Naldini L et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
4. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
5. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72: 811-816.
6. Zufferey R et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
7. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Therapy 1998; 5: 1481-1487.
8. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-357.
9. Clabough DL et al. Immune-mediated thrombocytopenia in horses infected with equine infectious anemia virus. J Virol 1991; 65: 6242-6251.
10. Maury W. Monocyte maturation controls expression of equine infectious anemia virus. J Virol 1994; 68: 6270-6279.
11. Maury W. Regulation of equine infectious anemia virus expression. J Biomed Sci 1998; 5: 11-23.
12. Maury WJ, Carpenter S, Graves K, Chesebro B. Cellular and viral specificity of equine infectious anemia virus Tat transactivation. Virology 1994; 200: 632-642.
13. Derse D, Newbold SH. Mutagenesis of EIAV TAT reveals structural features essential for transcriptional activation and TAR element recognition. Virology 1993; 194: 530-536.
14. Martarano L, Stephens R, Rice N, Derse D. Equine infectious anemia virus trans-regulatory protein Rev controls viral mRNA stability, accumulation, and alternative splicing. J Virol 1994; 68: 3102-3111.
15. Belshan M et al. Biological characterization of Rev variation in equine infectious anemia virus. J Virol 1998; 72: 4421-4426.
16. Schiltz RE et al. Equine infectious anemia virus gene expression: characterization of the RNA splicing pattern and the protein products encoded by open reading frames S1 and S2. J Virol 1992; 66: 3455-3465.
17. Elder JH et al. Distinct subsets of retroviruses encode dUTPase. J Virol 1992; 66: 1791-1794.
18. Lichtenstein DL et al. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity. J Virol 1995; 69: 2881-2888.
19. Steagall WK et al. Incorporation of uracil into viral DNA correlates with reduced replication of EIAV in macrophages. Virology 1995; 210: 302-313.
20. Threadgill DS et al. Characterization of equine infectious anemia virus dUTPase: growth properties of a dUTPase-deficient mutant. J Virol 1993; 67: 2592-2600.
21. Vertessy BG et al. Specific derivatization of the active site tyrosine in dUTPase perturbs ligand binding to the active site. Biochem Biophys Res Commun 1996; 219: 294-300.
22. Turelli P et al. Replication properties of dUTPase-deficient mutants of caprine and ovine lentiviruses. J Virol 1996; 70: 1213-1217.
23. Turelli P et al. dUTPase-minus caprine arthritis-encephalitis virus is attenuated for pathogenesis and accumulates G-to-A substitutions. J Virol 1997; 71: 4522-4530.
24. Payne SL et al. Characterization of infectious molecular clones of equine infectious anaemia virus. J Gen Virol 1994; 75: 425-429.
25. Soneoka Y et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
26. Montelaro RC, Parekh B, Orrego A, Issel CJ. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J Biol Chem 1984; 259: 10539-10544.
27. Burns JC et al. Vesicular stomatitis virus G glycoportein pseudo-typed retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033-8037.
28. Mullen RJ, Buck CR, Smith AM. Neu N, a neuronal specific nuclear protein in vertebrates. Development 1992; 116: 201-211.
29. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994; 68: 510-516.
30. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992; 11: 3053-3058.
31. Bukrinsky MI et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 365; 666-669.
32. von Schwedler U, Kornbluth RS, Trono D. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 1994; 91: 6992-6996.
33. Gallay P et al. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 1996; 70: 1027-1032.
34. Gallay P, Hope T, Chin D, Trono D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci USA 1997; 94: 9825-9830.
35. Heinzinger NK et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91: 7311-7315.
36. Li F, Puffer BA, Montelaro RC. The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J Virol 1998; 72: 8344-8348.
37. McIntosh EM, Haynes RH. HIV and human endogenous retroviruses: an hypothesis with therapeutic implications. Acta Biochim Pol 1996; 43: 583-592.
38. Lerner DL et al. Increased mutation frequency of feline immunodeficiency virus lacking functional deoxyuridine-triphosphatase. Proc Natl Acad Sci USA 1995; 92: 7408-7484.
39. Fielding AK et al. Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood 1998; 91: 1802-1809.
40. Martin F et al. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope. Hum Gene Ther 1998; 9: 737-746.
41. Bray M et al. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci USA 1994; 91: 1256-1260.
42. Srinivasakumar N et al. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 1997; 71: 5841-5848.
43. von Gegerfelt A, Felber BK. Replacement of posttranscriptional regulation in SIVmac239 generated a Rev-independent infectious virus able to propagate in rhesus peripheral blood mononuclear cells. Virology 1997; 232: 291-299.
44. Albini A et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994; 8: 1237-1244.
45. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993; 90: 7941-7945.
46. Albini A et al. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad SCi USA 1995; 92: 4838-4842.
47. Albini A et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogeue 1996; 12: 289-297.
48. Jowett JB et al. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 1995; 69: 6304-6313.
49. Wood MJ et al. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Therapy 1994; 1: 283-291.
50. Zeman W, Innes JRM. Craigie's Neuroanatomy of the Rat. Academic Press: New York, London, 1963.